Manning & Napier Advisors LLC Increases Stake in Cellebrite DI Ltd. $CLBT

Manning & Napier Advisors LLC grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 156.3% during the 3rd quarter, Holdings Channel reports. The fund owned 151,320 shares of the company’s stock after buying an additional 92,270 shares during the period. Manning & Napier Advisors LLC’s holdings in Cellebrite DI were worth $2,804,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. Voss Capital LP raised its holdings in Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after purchasing an additional 1,306,398 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its position in Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after buying an additional 570,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after buying an additional 209,473 shares during the period. Pertento Partners LLP lifted its position in shares of Cellebrite DI by 11.8% during the 2nd quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after buying an additional 309,988 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Cellebrite DI by 61.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock valued at $39,200,000 after acquiring an additional 931,300 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 2.5%

NASDAQ:CLBT opened at $17.55 on Thursday. The business’s 50-day moving average is $17.86 and its 200 day moving average is $16.92. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The company has a market capitalization of $4.20 billion, a P/E ratio of 56.61, a P/E/G ratio of 2.51 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The firm’s revenue was up 17.9% on a year-over-year basis. During the same period last year, the company earned $0.14 earnings per share. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Lake Street Capital raised their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Bank of America raised their price target on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC upped their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.